The most widely used immunotherapy in CRC is the immune checkpoint inhibitors (ICIs), which included PD-1/PD-L1 inhibitors and cytotoxic T-lymphocyte antigen 4 (CTLA-4) inhibitors. This evidence concerns the gene CD274 and colorectal carcinoma.